









Markets
/
Stocks
/
nasdaq-cmnd
/

Clearmind Medicine Inc

CMND

0.774USD

-0.037-4.51%

Close 11/04, 16:00（ET）Quotes delayed by 15 min

4.16MMarket Cap

LossP/E TTM



Clearmind Medicine Inc

0.774

-0.037-4.51%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Clearmind Medicine Inc

Currency: USD Updated: 2025-10-27

Key Insights

Its valuation is considered undervalued,and institutional recognition is very high. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Clearmind Medicine Inc's Score

Industry at a Glance

Industry Ranking

308 / 501

Overall Ranking

623 / 4682

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 0 analysts

Current Rating

Target Price

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Clearmind Medicine Inc Highlights

StrengthsRisks

Clearmind Medicine Inc. is a psychedelic pharmaceutical biotech company. The Company is focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorders. The Company researches and develops psychedelic-based compounds and attempts to commercialize them as regulated medicines, foods, or supplements. The Company’s intellectual portfolio consists of 15 patent families, including 27 granted patents and 24 pending applications. The portfolio spans a range of jurisdictions, including the United States, Europe, India, and China.

Undervalued

The company’s latest PE is -1.32, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 589.42K shares, decreasing 42.22% quarter-over-quarter.

Held by Joel Greenblatt

Star Investor Joel Greenblatt holds 344.52K shares of this stock.

Financial Health

Currency: USD Updated: 2025-10-27

There is no financial score for this company; the Biotechnology & Medical Research industry's average is 6.92.

Score

Industry at a Glance

Previous score

0.00

Change



Financials



Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings



Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency



Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential



Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns



Key Metrics

Free cash flow

No Data

Clearmind Medicine Inc's Company Valuation

Currency: USD Updated: 2025-10-27

The company’s current valuation score is 7.97, which is higher than the Biotechnology & Medical Research industry's average of 6.98. Its current P/E ratio is -1.32, which is -43.30% below the recent high of -0.75 and -9.54% above the recent low of -1.44.

Score

Industry at a Glance

Previous score

7.97

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 308/501

No Data

Earnings Forecast

Currency: USD Updated: 2025-10-27

There is no earnings forecast score for this company; the Biotechnology & Medical Research industry's average is 8.04.

Score

Industry at a Glance

Previous score

0.00

Change

Support & Resistance

No Data

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-10-27

The company’s current price momentum score is 1.28, which is lower than the Biotechnology & Medical Research industry's average of 6.80. Sideways: Currently, the stock price is trading between the resistance level at 1.08 and the support level at 0.92, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

1.29

Change

-0.01

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.045

Sell

RSI(14)

29.940

Sell

STOCH(KDJ)(9,3,3)

9.925

Oversold

ATR(14)

0.078

High Vlolatility

CCI(14)

-153.555

Sell

Williams %R

94.756

Oversold

TRIX(12,20)

-0.402

Sell

StochRSI(14)

0.000

Oversold

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

0.857

Sell

MA10

0.927

Sell

MA20

0.949

Sell

MA50

0.997

Sell

MA100

0.988

Sell

MA200

1.052

Sell

Institutional Confidence

Currency: USD Updated: 2025-10-27

The company’s current institutional recognition score is 3.00, which is lower than the Biotechnology & Medical Research industry's average of 5.11. The latest institutional shareholding proportion is 10.96%, representing a quarter-over-quarter decrease of 23.27%. The largest institutional shareholder is Joel Greenblatt, holding a total of 344.52K shares, representing 6.40% of shares outstanding, with 18.13% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Gotham Asset Management, LLC

Star Investors

344.52K

+0.32%

AdvisorShares Investments, LLC

205.93K

-6.79%

Shani (Adi Zuloff)

54.23K

+3153.45%

Weiss (Amitay)

39.83K

-27.76%

Rootenberg (Alan)

24.75K

+161.59%

Shachar (Yehonatan Samuel)

12.50K

Itzhaik (Asaf)

12.50K

XTX Markets LLC

11.52K

J.P. Morgan Securities LLC

3.54K

Morgan Stanley Smith Barney LLC

2.56K

Risk Assessment

Currency: USD Updated: 2025-10-27

There is no risk assessment score for the company; the Biotechnology & Medical Research industry's average is 3.49. The company's beta value is -1.23. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.